Intravesical Recombinant Mycobacterium (rMBCG)

Phase 2Biologic

Intravesical Recombinant Mycobacterium (rMBCG) is one of 3 biologic programs targeting Mycobacterium. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MycobacteriumNot yet recruiting

MycobacteriumPhase 2

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Mycobacterium

#DrugCompanyPhaseTrials

Intravesical Recombinant Mycobacterium (rMBCG)

IImmunityBio, Inc.

Phase 2

1 2

Arikayce

IInsmed Incorporated

Phase 2

1 3

Viroptic

MMonarch Medical Research

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1/2Not yet recruiting

Mycobacterium

NCT06800963

Clinical

Trials by Indication[1]

Mycobacterium1 trial

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

Not yet recruiting·IImmunityBio, Inc.·Phase 1/2·NCT06800963·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intravesical Recombinant Mycobacterium (rMBCG). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intravesical Recombinant Mycobacterium (rMBCG) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intravesical Recombinant Mycobacterium (rMBCG). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ImmunityBio, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: IImmunityBio, Inc.

Intravesical Recombinant Mycobacterium (rMBCG)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Mycobacterium1 trial

References

Drug Info

Quick Facts

Related News